ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Clinical impact following the establishment of a specialized brain metastases tumor board.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of brain metastasis tumor board (BMTB) on treatment patterns and survival.
methods365 patients with brain metastases (BM) were analyzed at the Hospital Clínic de Barcelona from October 2019 to October 2022. This included those treated in the department of neurosurgery and radiation oncology during the first 18 months following its establishment. Demographic, clinicopathological, and treatment data were recorded and compared between the groups with and without BTBM.
resultsOf 365, 95 were in the BMTB group and 270 in the non-BMTB group. Patients discussed at the BMTB had higher rates of surgery (53.7% vs. 14.7%, p < 0.001) and stereotactic radiosurgery (63.1% vs. 21.6%, p < 0.001). The time between surgical treatment and adjuvant radiotherapy was shorter in the BMTB group (37 days, 95% CI 4 vs. 48 days, 95% CI 18, p = 0.018). No differences were observed in local progression (26.0% vs. 20.8%, p = 0.9) but there were differences in cerebral progression (43.2% vs. 27.4%, p = 0.004). Rescue treatment was more common in the BMTB group (26.3% vs 10.0%, p < 0.001). Median survival after BM was significantly longer in the BMTB group (28.2 ± 2.7 vs. 12.7 ± 1.04 months, p < 0.001).
conclusionMultidisciplinary discussions for patients with BM are crucial as they improve overall survival through integrated therapies. Additional trials are needed to optimize treatment integration in this complication.
Indexed as
Identifiers
40549125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.